Versartis, Inc. (VSAR) Files Form 4 Insider Selling : Joshua T Brumm Sells 1,265 Shares

Versartis, Inc. (VSAR): Joshua T Brumm , Chief Financial Officer of Versartis, Inc. sold 1,265 shares on May 20, 2016. The Insider selling transaction was reported by the company on May 20, 2016 to the Securities and Exchange Commission. The shares were sold at $7.87 per share for a total value of $9,955.55 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 25, 2016, Paul Westberg (Sr. VP, Business Development) sold 1,430 shares at $9.68 per share price.On Jan 4, 2016, Joshua T Brumm (Chief Financial Officer) sold 990 shares at $12.44 per share price.Also, On Nov 13, 2015, R Scott Greer (director) purchased 10,000 shares at $10.16 per share price.On Apr 16, 2015, Jeffrey L Cleland (President and CEO) sold 8,000 shares at $20.13 per share price.

Shares of Versartis Inc (VSAR) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.27 points or -3.33% at $7.85 with 35,249 shares getting traded. Post opening the session at $8.05, the shares hit an intraday low of $7.63 and an intraday high of $8.328 and the price vacillated in this range throughout the day. The company has a market cap of $231,018 M and the number of outstanding shares has been calculated to be 29,42,90,00,000 shares. The 52-week high of Versartis Inc is $22.655 and the 52-week low is $6.17.

Versartis Inc Money Flow Index Chart

Versartis Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone VRS-317 for growth hormone deficiency (GHD) an orphan disease. The Company’s products include VRS-317 and XTEN Technology. VRS-317 combines the rhGH amino acid sequence utilized in rhGH products with a half-life extension technology XTEN to enable less frequent administration. The Company has initiated a Phase III clinical study of VRS-317 in pediatric growth hormone deficient patients. XTEN is a recombinant polypeptide that when genetically fused to a therapeutic payload of interest extends the in vivo half-life of these peptides and proteins in a tunable manner.

Leave a Reply

Versartis Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Versartis Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.